1996
DOI: 10.1006/bbrc.1996.1519
|View full text |Cite
|
Sign up to set email alerts
|

Urokinase Antisense Oligodeoxynucleotides as a Novel Therapeutic Agent for Malignant Glioma:In Vitroandin VivoStudies of Uptake, Effects and Toxicity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0

Year Published

1997
1997
2006
2006

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 23 publications
(18 citation statements)
references
References 0 publications
0
16
0
Order By: Relevance
“…Studies of intraventricular phosphorothioate ODN infusion lasting 1 week did not show any evidence of toxicity, yet the ODNs permeated the brain extensively and were taken up by astrocytes [60,62]. Other investigators have confirmed the superiority of phosphorothioate ODNs for CNS administration, the cellular uptake and biodistribution of intracranially administered ODNs, and their apparent lack of adverse effects [16,[63][64][65][66]. ODNs may be more stable within the CNS than in other bodily compartments [67].…”
Section: Odn Targeting Of Brain Tumorsmentioning
confidence: 84%
See 4 more Smart Citations
“…Studies of intraventricular phosphorothioate ODN infusion lasting 1 week did not show any evidence of toxicity, yet the ODNs permeated the brain extensively and were taken up by astrocytes [60,62]. Other investigators have confirmed the superiority of phosphorothioate ODNs for CNS administration, the cellular uptake and biodistribution of intracranially administered ODNs, and their apparent lack of adverse effects [16,[63][64][65][66]. ODNs may be more stable within the CNS than in other bodily compartments [67].…”
Section: Odn Targeting Of Brain Tumorsmentioning
confidence: 84%
“…Animal studies of ODN biodistribution have shown that ODNs administered systemically (as negatively charged molecules of approximately 5 kDa) enter the brain only in extremely small quantities [5,32,37,58,59]. Because of this, direct injection (or osmotic minipump infusion) into the CSF, brain parenchyma or tumor bed has been advocated [4,10,16,18,60,61]. Figure 3 shows a nude rat being implanted subcutaneously with an Alizet TM osmotic minipump, for the purpose of delivering antisense ODNs directly into the bed of an implanted brain tumor.…”
Section: Odn Targeting Of Brain Tumorsmentioning
confidence: 99%
See 3 more Smart Citations